Cardiff Oncology Inc (CRDF) Stock: More Strategic Than Meets the Eye

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]

Cardiff Oncology Inc (CRDF) Stock Surge: The Transparent Factors Exposed

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]

Why Did Cardiff Oncology Inc (CRDF) Stock See 17.12% Surge in the Last 90 Days?

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]

CRDF Unveiled: The Shocking Truth Behind Cardiff Oncology Inc’s Latest Stock Movements

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]

Why Did Cardiff Oncology Inc (CRDF) Stock Plunge -1.17% Last Week?

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]